[Cause and prevention of nocturnal gastric acid breakthrough].
Adachi
Kyoichi
K
Department of Internal Medicine II, Shimane Medical University.
Kinoshita
Yoshikazu
Y
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001189:Aryl Hydrocarbon Hydroxylases; D001562:Benzimidazoles / Q000494:pharmacology / Q000627:therapeutic use; D002940:Circadian Rhythm; D065731:Cytochrome P-450 CYP2C19; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics; D004942:Esophagitis, Peptic / Q000209:etiology; D005744:Gastric Acid / Q000378:metabolism*; D016481:Helicobacter Infections / Q000503:physiopathology; D016480:Helicobacter pylori; D006635:Histamine H2 Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D064747:Lansoprazole; D006899:Mixed Function Oxygenases / Q000235:genetics; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000502:physiology; D064750:Rabeprazole; D011899:Ranitidine / Q000627:therapeutic use
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D054328:Proton Pump Inhibitors; D017494:Proton Pumps; D064747:Lansoprazole; D064750:Rabeprazole; D011899:Ranitidine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole